(Sharecast News) - A treatment for rectal cancer being developed by GSK has shown positive results in interim testing, the pharma giant announced on Monday.
Jemperli, the brand name of immunotherapy drug dostarlimab, met its primary objective in an interim analysis of a registrational phase II trial in patients with stage...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE